goodrx stock overview and investor guide
GoodRx Holdings, Inc. (goodrx stock / GDRX)
As of January 27, 2026, according to Yahoo Finance and MarketWatch, goodrx stock (ticker: GDRX) represents GoodRx Holdings, Inc., a U.S.-based digital healthcare company focused on prescription savings and telehealth services. This article explains GoodRx’s business lines, financial profile, stock information, analyst coverage, governance, competitive position, risks, and where investors and researchers can find authoritative public filings and market data.
What you will learn: a clear, neutral overview of goodrx stock, how the company makes money, the primary products and partnerships that matter to the business, common financial metrics to watch, and resources to validate up-to-date market figures.
Company overview
GoodRx is a U.S. digital healthcare company that operates a consumer-facing prescription marketplace and provides telehealth and business-to-business services. The company helps individuals find prescription price comparisons and discounts at participating pharmacies, offers subscription programs for deeper savings, provides telemedicine consultations, and supplies manufacturer-, pharmacy-, and PBM-facing solutions that support drug access and patient engagement.
GoodRx is headquartered in Santa Monica, California. Its stated mission emphasizes lowering out-of-pocket prescription costs and improving access to affordable care through technology and partnerships. In public markets, goodrx stock trades on the Nasdaq under the ticker GDRX.
As of January 27, 2026, according to MarketWatch, GoodRx continued to operate a hybrid consumer- and partner-oriented model that blends advertising, referral/transaction revenue, subscription fees, and telehealth charges.
Products and services
Prescription price marketplace and discount tools
GoodRx’s core consumer product is a prescription price-comparison marketplace. Consumers enter a medication and ZIP code to view available prices at local pharmacies and digital option comparisons. GoodRx aggregates pharmacy cash prices and negotiated discounts and presents coupons, savings cards, and discount codes consumers can use at checkout. These price-discovery tools are central to goodrx stock’s consumer engagement and referral revenue.
Subscription offerings (GoodRx Gold and related plans)
GoodRx offers subscription plans (historically marketed under names such as GoodRx Gold and similar tiers) that provide members with deeper discounts and a broader network of participating pharmacies for a recurring fee. Subscription income contributes to more predictable recurring revenue for the company, though membership retention and acquisition costs directly influence margin dynamics.
Telehealth and virtual care
GoodRx’s telemedicine services include on-demand virtual consultations for certain conditions and prescriptions. Telehealth fees and related clinical service revenues are an expanding part of the company’s consumer-revenue mix and are positioned to leverage the existing prescription-savings user base.
Business-to-business offerings
On the partner side, GoodRx provides services to drug manufacturers, pharmacies, and benefit managers. These services include patient acquisition solutions, co-pay and coupon programs, analytics, and tools intended to help product launches and adherence programs. B2B revenues are typically driven by commercial agreements, performance-based fees, and platform integrations.
History
Founding and early growth
GoodRx was founded to solve the problem of opaque prescription pricing in the U.S. market. The platform gained early traction by offering free price comparison tools and printable coupons that drove consumer adoption and frequent site visits. The initial product rollout focused on usability and rapid expansion of participating pharmacies and coupon partnerships.
Funding and private-stage milestones
Before going public, GoodRx completed multiple private funding rounds and formed strategic partnerships to scale its technology, expand pharmacy integration, and broaden marketing reach. Venture funding and partnerships helped build the marketplace infrastructure and the data assets that underpin GoodRx’s price-comparison functionality.
Public listing (IPO)
GoodRx pursued a public listing to access capital for product expansion and to provide liquidity for early investors. The company listed on the Nasdaq under the ticker GDRX. The IPO allowed GoodRx to accelerate investments in telehealth, subscription offerings, and B2B solutions while increasing public disclosure through SEC filings.
As of January 27, 2026, public-market coverage and reporting on goodrx stock remain active across major financial media and market-data providers, including Yahoo Finance, MarketWatch, CNBC, and Zacks.
Business model and revenue streams
GoodRx’s business model is diversified across consumer- and partner-facing revenue streams. Key components include:
- Referral/transaction fees: When consumers use GoodRx coupons or are referred to pharmacies, GoodRx may earn fees tied to transactions or referral volumes.
- Subscription income: Monthly or annual subscription plans (e.g., GoodRx Gold historically) provide recurring revenue and deeper discounts to members.
- Telehealth fees: Charges for virtual consultations and clinical services contribute to fee-for-service revenue.
- B2B services: Agreements with drug manufacturers, pharmacies, and PBMs for patient acquisition, coupon distribution, data analytics, and adherence initiatives generate commercial revenue.
- Advertising and data-driven services: Monetization of the platform’s audience through advertising, sponsored listings, and insights sold to partners adds another dimension to the revenue mix.
The interplay among these streams means the company’s revenue growth and margins depend on consumer traffic, conversion to paid memberships, telehealth utilization, and success in commercial partnerships.
Financial performance
This section summarizes the types of financial information that matter to researchers and investors. It emphasizes high-level trends and where to find the most recent validated figures.
As of January 27, 2026, according to Yahoo Finance and MarketWatch, GoodRx’s financial profile shows revenue driven by a blend of subscription, telehealth, and partner revenues. Specific quarter-to-quarter metrics and guidance are available in the company’s SEC filings and investor presentations.
Key financial metrics to monitor
- Revenue and revenue growth rates (year-over-year and quarter-over-quarter)
- Net income or net loss and adjusted profitability measures (e.g., adjusted EBITDA)
- Gross margin and contribution margin by product line
- Free cash flow and operating cash flow
- Cash, short-term investments, and debt levels on the balance sheet
- Subscriber counts and average revenue per subscriber for subscription offerings
- Telehealth visit volumes and average revenue per visit
- B2B contract backlog and revenue visibility
When assessing goodrx stock, analysts commonly track these metrics and reference consensus estimates from providers such as Zacks and MarketWatch.
Quarterly and annual results
GoodRx reports results in quarterly (10-Q) and annual (10-K) SEC filings and through earnings releases and calls. Typical reporting highlights include revenue and adjusted EBITDA, user-engagement metrics (monthly active users or MAUs), membership counts for subscription services, telehealth visit volumes, and commentary on guidance.
Investors should note seasonality or one-off items that can affect results. For example, promotional campaigns, changes to pharmacy networks, or one-time legal settlements can influence quarterly comparability. For the most current quarter results, consult the latest 8-K, earnings release, and investor presentation.
Stock information
Ticker, exchange, share classes, and ISIN
- Ticker: GDRX
- Exchange: Nasdaq
- Share classes: Common shares (publicly traded)
- ISIN: Investors should confirm the ISIN and other security identifiers in the company’s investor relations materials and SEC filings for exact reference.
Trading history and performance
goodrx stock has historically experienced volatility common to growth-oriented technology and healthcare platforms. Price movements reflect changes in revenue growth expectations, margin outlook, telehealth adoption trends, regulatory news, and broader market sentiment toward healthcare technology stocks.
As of January 27, 2026, market-data providers such as Yahoo Finance, TradingView, and MarketWatch provide up-to-date historical charts, 52-week ranges, and return figures for GDRX that investors can consult to analyze performance over different time horizons.
Market capitalization and shareholder base
GoodRx is typically classified within small- to mid-cap market-cap ranges depending on current price levels. Institutional ownership is commonly reported by market-data services; large asset managers and index funds often appear among the top institutional holders. For an authoritative list of major shareholders and insider ownership, review the company’s proxy statements and market-data summaries.
Dividends, splits, and corporate actions
Historically, GoodRx has prioritized reinvestment in growth initiatives and has not maintained a regular dividend policy. Any stock splits, repurchases, or material capital-structure decisions are announced via 8-K filings and investor relations communications. Investors should check the most recent SEC filings for current corporate action history.
Analyst coverage and market consensus
GoodRx receives analyst coverage from sell-side and independent research providers. Major market-data platforms aggregate analyst ratings and price targets to present a consensus view (e.g., Buy/Hold/Sell distribution and average price target). Analysts typically focus on subscriber growth, telehealth monetization, B2B contract trends, margin expansion, and regulatory risk.
As of January 27, 2026, summaries of analyst ratings, price-target ranges, and recent upgrades or downgrades are available on platforms such as Zacks, CNBC, and MarketWatch. Analysts’ viewpoints may diverge widely; therefore, consensus figures and recent changes should be examined alongside the firm’s publicly disclosed guidance.
Corporate governance and management
GoodRx’s executive team and board composition are important for governance assessment. Typical items to review include:
- CEO profile and tenure, strategic priorities, and previous experience
- CFO and finance leadership experience and track record on financial reporting and capital allocation
- Board independence, committee structure (audit, compensation, nominating/governance), and any recent board changes
- Executive compensation structure and links to performance metrics
For up-to-date leadership biographies and governance documents, consult the company’s investor relations site and proxy statement filed with the SEC.
Partnerships, acquisitions, and strategic initiatives
GoodRx has pursued partnerships with pharmacies, pharmacy chains, drug manufacturers, and healthcare platforms to expand its price-discovery network and B2B offerings. Strategic acquisitions historically focused on expanding telehealth capabilities, analytics, or complementary consumer-health offerings.
Major partnerships and acquisitions are communicated through press releases and 8-K filings; these events can materially affect revenue mix, costs, and long-term strategic positioning for goodrx stock.
Competition and market position
Primary competitive categories include prescription savings platforms, telehealth providers, and broader healthcare-technology companies that address drug access and patient affordability. Competitive dynamics are driven by network reach (pharmacies and insurers), pricing relationships, product ease-of-use, data assets, and brand recognition.
GoodRx’s competitive strengths often cited are a large consumer audience for prescription price discovery, an established coupon network, and cross-sell opportunities into telehealth and subscription services. Threats include increased competition from other digital health players, changes in pharmacy reimbursement practices, regulatory shifts that affect pricing transparency, and large incumbent healthcare players establishing or expanding competing offerings.
Risks and controversies
When evaluating goodrx stock, consider the following categories of risk:
- Regulatory and legislative risk: Changes to rules affecting drug pricing transparency, pharmacy reimbursement, or coupon validity can materially affect the business model.
- Legal and compliance risk: Litigation, class-action suits, or government inquiries related to pricing practices or commercial agreements can impose costs and create disclosure risk.
- Commercial concentration and partner risk: Reliance on a subset of pharmacy or manufacturer relationships could affect revenue if contracts change.
- Operational risks: Technology outages, data breaches, or telehealth clinical liabilities could disrupt services and damage reputation.
- Market and macro risk: Broader investor sentiment toward growth stocks, interest rates, and healthcare policy developments affect valuation and stock volatility.
As of January 27, 2026, reputable news outlets and financial-data providers continue to report developments in these areas; readers should review the latest 8-K filings and press coverage for current issues.
Investor relations and filings
Official sources for validated financial and corporate information include:
- SEC filings (Form 10-K for annual results, Form 10-Q for quarterly results, Form 8-K for material events, and proxy statements)
- Company investor relations website for earnings releases, slide decks, and webcasts
- Public filings accessible via the SEC’s EDGAR system
As of January 27, 2026, the most reliable method to confirm historic and current figures for goodrx stock is to consult the company’s most recent 10-K, most recent 10-Q, and the latest investor presentation.
See also
- Telehealth companies and virtual-care platforms
- Pharmacy benefit managers (PBMs) and their role in prescription pricing
- Healthcare technology stocks and digital health marketplaces
References and primary sources
This guide draws on market-data and media coverage commonly used for publicly traded companies. Key sources to consult for up-to-date information about goodrx stock include Yahoo Finance, MarketWatch, CNBC, CNN Markets, Zacks, The Motley Fool, Robinhood’s market summaries, StockTwits for market sentiment, and TradingView for charting and technical data. For legal and financial disclosure, refer to the company’s SEC filings and investor relations announcements.
- As of January 27, 2026, according to Yahoo Finance, GoodRx’s trading data and market summaries provide current price, volume, and market-cap indicators.
- As of January 27, 2026, according to MarketWatch, GoodRx’s corporate profile and recent headlines are summarized for investors.
- As of January 27, 2026, CNBC and CNN Markets provide analyst commentary and market coverage of GDRX.
- Zacks and The Motley Fool offer analyst-oriented notes and company overviews relevant for background research.
(Readers should consult the original sources directly for time-sensitive figures and to validate the most recent numbers.)
Practical next steps and resources
If you want to follow goodrx stock or research the company in depth:
- Review the most recent Form 10-K and Form 10-Q on the SEC EDGAR site for audited, detailed financial statements and MD&A commentary.
- Read the latest earnings press release and listen to the earnings call transcript for management’s tone on guidance and execution.
- Check market-data pages (Yahoo Finance, MarketWatch, TradingView) for real-time quotes, historical charts, and analyst consensus figures.
- Track regulatory and industry news that could affect prescription pricing dynamics and telehealth policy.
- For trading or custody, consider trusted platforms; for users of Web3 wallets or digital-asset interfaces, Bitget Wallet is available for related wallet and custody services. If you plan to trade or monitor markets on an exchange, use Bitget for order execution and account services as applicable.
Further exploration
To explore more about goodrx stock and linked healthcare-technology trends, consult the sources named in this article and review GoodRx’s investor relations materials. For trading or custody needs or to integrate wallet services, explore Bitget and Bitget Wallet for supported features and platform details.
Note: This article is informational and neutral in tone. It is not investment advice. For actionable investment decisions, consult licensed financial advisors and verify numbers via official filings and reputable market-data providers.
